Perrigo Company plc Payments to Acquire Other Productive Assets
Perrigo Company plc (PRGO) reported Payments to Acquire Other Productive Assets of $0 for the 9-month period ending 2023-09-30, per its 10-Q filed 2023-11-07.
Discontinued › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireOtherProductiveAssets · last filed 2023-11-07
- Perrigo Company plc payments to acquire other productive assets for the quarter ending 2023-09-30 was $0.00, a 100.00% decline year-over-year.
- Perrigo Company plc payments to acquire other productive assets for the quarter ending 2022-10-01 was $300.00K.
- Perrigo Company plc payments to acquire other productive assets for the quarter ending 2022-07-02 was $10.00M, a 3233.33% increase year-over-year.
- Perrigo Company plc payments to acquire other productive assets for the quarter ending 2022-04-02 was $0.00, a 100.00% decline year-over-year.
- Perrigo Company plc payments to acquire other productive assets for fiscal 2021 was $70.60M, a 100.57% increase from fiscal 2020.
- Perrigo Company plc payments to acquire other productive assets for fiscal 2020 was $35.20M, a 76.39% decline from fiscal 2019.
- Perrigo Company plc payments to acquire other productive assets for fiscal 2019 was $149.10M, a 318.82% increase from fiscal 2018.
- Perrigo Company plc payments to acquire other productive assets for fiscal 2018 was $35.60M.
| Period end | Payments to Acquire Other Productive Assets 3 month | Payments to Acquire Other Productive Assets 6 month | Payments to Acquire Other Productive Assets 9 month | Payments to Acquire Other Productive Assets 12 month |
|---|---|---|---|---|
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | $0.00 10-Q · filed 2023-11-07 | ||
| 2023-07-01 | $0.00 10-Q · filed 2023-08-08 | |||
| 2022-10-01 | $300.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | $10.30M derived: sum of 2 quarters · filed 2023-11-07 | $10.30M 10-Q · filed 2023-11-07 | $10.30M derived: sum of 4 quarters · filed 2023-11-07 |
| 2022-07-02 | $10.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | $10.00M 10-Q · filed 2023-08-08 | $10.00M derived: sum of 3 quarters · filed 2023-08-08 | $10.00M derived: sum of 4 quarters · filed 2023-08-08 |
| 2022-04-02 | $0.00 10-Q · filed 2022-05-11 | $0.00 derived: sum of 2 quarters · filed 2023-02-28 | $0.00 derived: sum of 3 quarters · filed 2023-02-28 | $300.00K derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $0.00 derived: sum of 2 quarters · filed 2023-02-28 | $300.00K derived: sum of 3 quarters · filed 2023-02-28 | $70.60M 10-K · filed 2023-02-28 |
| 2021-10-02 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | $300.00K derived: sum of 2 quarters · filed 2022-11-08 | $70.60M 10-Q · filed 2022-11-08 | $71.70M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-07-03 | $300.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | $70.60M 10-Q · filed 2022-08-09 | $71.70M derived: sum of 3 quarters · filed 2023-02-28 | $73.00M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-04-03 | $70.30M 10-Q · filed 2022-05-11 | $71.40M derived: sum of 2 quarters · filed 2023-02-28 | $72.70M derived: sum of 3 quarters · filed 2023-02-28 | $72.80M derived: sum of 4 quarters · filed 2023-02-28 |
| 2020-12-31 | $1.10M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $2.40M derived: sum of 2 quarters · filed 2023-02-28 | $2.50M derived: sum of 3 quarters · filed 2023-02-28 | $35.20M 10-K · filed 2023-02-28 |
| 2020-09-26 | $1.30M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-12 | $1.40M derived: sum of 2 quarters · filed 2021-11-12 | $34.10M 10-Q · filed 2021-11-12 | $97.00M derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-06-27 | $100.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-11 | $32.80M 10-Q · filed 2021-08-11 | $95.70M derived: sum of 3 quarters · filed 2022-03-01 | $146.90M derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-03-28 | $32.70M 10-Q · filed 2021-05-12 | $95.60M derived: sum of 2 quarters · filed 2022-03-01 | $146.80M derived: sum of 3 quarters · filed 2022-03-01 | $181.80M derived: sum of 4 quarters · filed 2022-03-01 |
| 2019-12-31 | $62.90M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | $114.10M derived: sum of 2 quarters · filed 2022-03-01 | $149.10M derived: sum of 3 quarters · filed 2022-03-01 | $149.10M 10-K · filed 2022-03-01 |
| 2019-09-28 | $51.20M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | $86.20M derived: sum of 2 quarters · filed 2020-11-05 | $86.20M 10-Q · filed 2020-11-05 | |
| 2019-06-29 | $35.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-05 | $35.00M 10-Q · filed 2020-08-05 | ||
| 2019-03-30 | $0.00 10-Q · filed 2020-05-05 | |||
| 2018-12-31 | $35.60M 10-K · filed 2021-03-01 | |||
| 2014-06-28 | $0.00 10-K · filed 2014-08-14 | |||
| 2013-06-29 | $0.00 10-K · filed 2014-08-14 | |||
| 2012-06-30 | $800.00K 10-K · filed 2014-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |